Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.
2 reports, 2 independent
Updated Aug 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Novo Nordisk licenses Lexicon's LX9851; Viatris files sotagliflozin.1 source
Sotagliflozin showed a promising clinical profile for Type 1 Diabetes.1 source
Keep exploring
The entities involved
-
Lexicon Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Novo Nordisk
Danish pharmaceutical company
-
Mylan
former pharmaceutical company
Related events
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- Novo Nordisk expanded its pediatric label franchise on September 15, 2026.
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.
Coverage
Newest first; wire copies grouped- GlobeNewswireLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results I
- Insider MonkeyH.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the hot penny stocks to invest in now. H.C. Wainwright analyst Joseph P